EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy

Ahizechukwu C Eke iD, Sean S Brummel, Muktar H Aliyu, Lynda Stranix-Chibanda, George U Eleje, Ifeanyichukwu U Ezebialu, Violet Korutaro, Deo Wabwire, Allen Matubu, Tapiwa Mbengeranwa, Nahida Chakhtoura, Lameck Chinula und 9 weitere

Clinical Infectious Diseases · 17.03.2025 · 80 (3) · 594-601

DOI: 10.1093/cid/ciae441 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 02.09.2024. Verfasst von Ahizechukwu C Eke und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Adenine, Anti-HIV Agents, Blood Glucose, HIV Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) regimens have been associated with adverse changes in lipid and glucose profiles compared with tenofovir disoproxil fumarate (TDF)-based ART, but data in pregnancy are limited. We evaluated metabolic markers in pregnant women with human immunodeficiency virus (HIV) after starting TAF- versus TDF-based ART.

Methods

We analyzed data within the IMPAACT 2010/VESTED trial, which demonstrated better pregnancy outcomes in pregnant women randomized to initiate TAF/Emtricitabine/Dolutegravir (TAF/FTC + DTG; n = 217) or TDF/FTC + DTG (n = 215). We measured non-fasting plasma concentrations of glucose, total-cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), lipoprotein (a), and triglycerides from samples collected 8 weeks after enrollment. We employed linear regression models to estimate by-arm mean differences.

Results

In total, 219 participants enrolled in the DTG arms in Zimbabwe and Uganda: 109 in the TAF/FTC + DTG and 110 in the TDF/FTC + DTG arms. At study entry, mean gestational age was 22.6 weeks, median HIV-1 RNA was 711 copies/mL, and mean age was 25.8 years. By 8 weeks, mean total cholesterol was 12 mg/dL higher in women randomized to TAF/ FTC + DTG versus TDF/FTC + DTG (95% confidence interval [CI]: 3.8, 21.1). Pregnant women in the TAF/FTC + DTG arm had higher mean LDL-C (7.1 mg/dL, 95% CI: .2, 14.0), triglycerides (12.3 mg/dL, 95% CI: 1.8, 22.7), lipoprotein (a) (7.3 mg/dL, 95% CI: 1.1, 13.6), and lower mean HDL-C (2.8 mg/dL, 95% CI: .1, 5.6) compared to the TDF/FTC + DTG arm.

Conclusions

Pregnant women randomized to start TAF/FTC + DTG had higher lipids than those randomized to TDF/FTC + DTG within 8 weeks of ART initiation. However, lipid levels were within normal reference ranges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAnti-HIV AgentsBlood GlucoseHIV InfectionsLipidsPregnancy Complications, InfectiousTenofovirAdultFemaleHumansPregnancyYoung AdultEmtricitabineUgandaZimbabweAlanine

Stichwörter der Autor:innen

HIVhyperlipidemiametabolic complicationspregnancytenofovir

Substanzen

AdenineAnti-HIV AgentsBlood GlucoseEmtricitabineLipidsTenofovirtenofovir alafenamideAlanine

Autor:innen und Institutionen

  • Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Health Policy and Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Child and Adolescent Health Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
  • Faculty of Medicine and Health Sciences, University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
  • Department of Obstetrics and Gynecology, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.

ORCID-Profile: Ahizechukwu C Eke, Todd Brown, Shahin Lockman

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • NIH HHS
  • NHLBI NIH HHS
  • NICHD NIH HHS
  • NIMH NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Network

Zitieren

APA

Eke, A. C., Brummel, S. S., Aliyu, M. H., Stranix-Chibanda, L., Eleje, G. U., Ezebialu, I. U., Korutaro, V., Wabwire, D., Matubu, A., Mbengeranwa, T., Chakhtoura, N., Chinula, L., McCarthy, K., Knowles, K., Krotje, C., Linton, M. F., Dooley, K. E., Sax, P. E., Brown, T., …, & IMPAACT 2010/VESTED Study Team (2025). Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy. Clinical Infectious Diseases, 80(3), 594-601. https://doi.org/10.1093/cid/ciae441

Vancouver

Eke AC, Brummel SS, Aliyu MH, Stranix-Chibanda L, Eleje GU, Ezebialu IU, et al. Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy. Clinical Infectious Diseases. 2025;80(3):594-601. doi:10.1093/cid/ciae441

BibTeX
@article{Eke2025,
  author = {Eke, Ahizechukwu C and Brummel, Sean S and Aliyu, Muktar H and Stranix-Chibanda, Lynda and Eleje, George U and Ezebialu, Ifeanyichukwu U and Korutaro, Violet and Wabwire, Deo and Matubu, Allen and Mbengeranwa, Tapiwa and Chakhtoura, Nahida and Chinula, Lameck and McCarthy, Katie and Knowles, Kevin and Krotje, Chelsea and Linton, Macrae F and Dooley, Kelly E and Sax, Paul E and Brown, Todd and Lockman, Shahin and IMPAACT 2010/VESTED Study Team, IMPAACT 2010/VESTED Study Team},
  title = {Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {3},
  pages = {594--601},
  doi = {10.1093/cid/ciae441}
}
Kostenlos starten →